Earliest radiological progression in glioblastoma by multidisciplinary consensus review
Open Access
- 18 May 2018
- journal article
- review article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 139 (3) , 591-598
Abstract
Background Detection of glioblastoma progression is important for clinical decision-making on cessation or initiation of therapy, for enrollment in clinical trials, and for response measurement in time and location. The RANO-criteria are considered standard for the timing of progression. To evaluate local treatment, we aim to find the most accurate progression location. We determined the differences in progression free survival (PFS) and in tumor volumes at progression (Vprog) by three definitions of progression. Methods In a consecutive cohort of 73 patients with newly-diagnosed glioblastoma between 1/1/2012 and 31/12/2013, progression was established according to three definitions. We determined (1) earliest radiological progression (ERP) by retrospective multidisciplinary consensus review using all available imaging and follow-up, (2) clinical practice progression (CPP) from multidisciplinary tumor board conclusions, and (3) progression by the RANO-criteria. Results ERP was established in 63 (86%), CPP in 64 (88%), RANO progression in 42 (58%). Of the 63 patients who had died, 37 (59%) did with prior RANO-progression, compared to 57 (90%) for both ERP and CPP. The median overall survival was 15.3 months. The median PFS was 8.8 months for ERP, 9.5 months for CPP, and 11.8 months for RANO. The PFS by ERP was shorter than CPP (HR 0.57, 95% CI 0.38–0.84, p = 0.004) and RANO-progression (HR 0.29, 95% CI 0.19–0.43, p < 0.001). The Vprog were significantly smaller for ERP (median 8.8 mL), than for CPP (17 mL) and RANO (22 mL). Conclusion PFS and Vprog vary considerably between progression definitions. Earliest radiological progression by retrospective consensus review should be considered to accurately localize progression and to address confounding of lead time bias in clinical trial enrollment.Keywords
Funding Information
- KWF Kankerbestrijding (VU2014-7113)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (10-10400-96-14003)
- NIHR-UCLH Biomedical Research Centre
This publication has 44 references indexed in Scilit:
- Application of Novel Response/Progression Measures for Surgically Delivered Therapies for GliomasNeurosurgery, 2012
- Response Assessment in Neuro-Oncology Criteria: Implementation Challenges in Multicenter Neuro-Oncology TrialsAmerican Journal of Neuroradiology, 2011
- Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancementEuropean Radiology, 2011
- The impact of symptom interference using the MD Anderson Symptom Inventory‐Brain Tumor Module (MDASI‐BT) on prediction of recurrence in primary brain tumor patientsCancer, 2011
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR ImagingRadiology, 2009
- Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastomaNeurology, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Multifaceted end points in brain tumor clinical trials: Cognitive deterioration precedes MRI progressionNeuro-Oncology, 2003
- Using Weighted Rankings in the Analysis of Complete Blocks with Additive Block EffectsJournal of the American Statistical Association, 1979